There is no doubt that the landscape of transcatheter aortic valve implantation (TAVI) has undergone significant transformation over the past 10–15 years. What was then an emerging therapy for those at truly prohibitive surgical risk is now an accepted (if not standard) therapy for a substantial proportion of patients across the full spectrum of clinical risk. Concomitant with this evolution has come a necessary and appropriate premium on longer-term outcomes. While survival and some degree of clinical improvement were satisfactory endpoints after TAVI for highly symptomatic patients with limited therapeutic options and dismal outcomes with conservative management, the fact that lower-risk individuals have a longer life expectancy and a viable surgical alternative raises the bar considerably. Of course, mortality, stroke, and major bleeding remain important, but multiple factors including valvular hemodynamics, aortic insufficiency (AI), and conduction abnormalities also warrant attention. These more subtle outcomes may eventually have significant impact. Accordingly, identifying markers that potentially reflect these issues and predict outcomes is intuitively attractive in that it can potentially inform decision making for optimization and can identify patients who may benefit from closer monitoring.